Literature DB >> 33983519

Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma.

Guillaume Chotard1, Maylis Capdepont2, Quentin Denost2, Denis Smith3, Véronique Vendrely4, Eric Rullier2, Anne Rullier5.   

Abstract

The pathological nodal stage, determination of which requires examination of ≥ 12 lymph nodes, is one of the main prognostic factors in rectal cancer. Neoadjuvant chemoradiotherapy (CRT) may reduce the number of both lymph nodes retrieved and positive lymph nodes. Induction chemotherapy before CRT aimed at reducing the rate of distant metastases. However, the impact of this new treatment on number of lymph nodes retrieved and positive lymph nodes is unknown. This study was performed to evaluate the effects of neoadjuvant chemotherapy on lymph nodes in locally advanced rectal cancer treated by CRT. We retrospectively included patients with T2 - 4 Nx M0 rectal cancer and compared those receiving neoadjuvant chemotherapy plus CRT with those receiving CRT alone. From 2012 to 2019, 85 patients were treated with neoadjuvant chemotherapy + CRT and 189 with CRT alone. The number of lymph nodes retrieved (19 vs. 17, respectively, P = 0.434), the rate of specimens with ≥ 12 lymph nodes (92% vs. 88%, respectively, P = 0.397), and the median number of positive lymph nodes (1 vs. 2, respectively, P = 0.878) were similar between the two groups. However, the rate of pN0 was higher after neoadjuvant chemotherapy + CRT compared to CRT (75% vs. 62%, respectively, P = 0.030). Neoadjuvant chemotherapy before CRT for locally advanced rectal cancer did not modify the number of lymph nodes retrieved or the number of positive lymph nodes compared to CRT alone. However, it significantly increased the rate of tumors without any positive lymph nodes (ypN0).

Entities:  

Keywords:  Induction chemotherapy; Lymph node; Radiochemotherapy; Rectal cancer; Total neoadjuvant treatment

Year:  2021        PMID: 33983519     DOI: 10.1007/s00428-021-03108-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  35 in total

1.  The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.

Authors:  Richard S Swanson; Carolyn C Compton; Andrew K Stewart; Kirby I Bland
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

2.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).

Authors:  Alice Dewdney; David Cunningham; Josep Tabernero; Jaume Capdevila; Bengt Glimelius; Andres Cervantes; Diana Tait; Gina Brown; Andrew Wotherspoon; David Gonzalez de Castro; Yu Jo Chua; Rachel Wong; Yolanda Barbachano; Jacqueline Oates; Ian Chau
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

Review 3.  Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.

Authors:  Anne J Breugom; Marloes Swets; Jean-François Bosset; Laurence Collette; Aldo Sainato; Luca Cionini; Rob Glynne-Jones; Nicholas Counsell; Esther Bastiaannet; Colette B M van den Broek; Gerrit-Jan Liefers; Hein Putter; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

Review 4.  Using a Lymph Node Count Metric to Identify Underperforming Hospitals After Rectal Cancer Surgery.

Authors:  Mustafa Raoof; Syed Nabeel Zafar; Philip H G Ituarte; Robert S Krouse; Kurt Melstrom
Journal:  J Surg Res       Date:  2018-12-20       Impact factor: 2.192

5.  Prognostic value of pathological node status after neoadjuvant radiotherapy for rectal cancer.

Authors:  E Duchalais; T Glyn Mullaney; G M Spears; S R Kelley; K Mathis; W S Harmsen; D W Larson
Journal:  Br J Surg       Date:  2018-04-17       Impact factor: 6.939

6.  Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Authors:  Jean-Pierre Gérard; Thierry André; Frédéric Bibeau; Thierry Conroy; Jean-Louis Legoux; Guillaume Portier; Jean-François Bosset; Guillaume Cadiot; Olivier Bouché; Laurent Bedenne
Journal:  Dig Liver Dis       Date:  2017-01-20       Impact factor: 4.088

7.  Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist.

Authors:  Eva Judith Ann Morris; Nicola Joanne Maughan; David Forman; Philip Quirke
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 8.  Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin.

Authors:  K Bujko; B Glimelius; V Valentini; W Michalski; M Spalek
Journal:  Eur J Surg Oncol       Date:  2015-04-13       Impact factor: 4.424

9.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

10.  The effect of neoadjuvant therapy on the size, number, and distribution of mesorectal lymph nodes.

Authors:  Gülçin Yegen; Metin Keskin; Melek Büyük; Enver Kunduz; Emre Balık; Esra Kaytan Sağlam; Yersu Kapran; Oktar Asoğlu; Mine Güllüoğlu
Journal:  Ann Diagn Pathol       Date:  2015-10-29       Impact factor: 2.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.